Effectiveness of Sugammadex on muscle relaxant reversal in preterm neonates

References

• Chaves-Cardona H, Hernandez-Torres V, Kiley S, et al. Neuromuscular blockade management in patients with COVID-19. Korean J Anesthesiol. 2021 Aug 1;74(4):285–292.
   PubMed Web of Science ®Google Scholar
• Baillard C, Clec’h C, Catineau J, et al. Postoperative residual neuromuscular block: a survey of management. Br J Anaesth. 2005 Nov 1;95(5):622–626.
   PubMed Web of Science ®Google Scholar
• Nag K, Singh DR, Shetti AN, et al. A revolutionary drug in neuromuscular pharmacology. Anesthesia, essays and research. 2013 Sep;7(3): 302.
   PubMedGoogle Scholar
• Kovac AL. Sugammadex: the first selective binding reversal agent for neuromuscular block. J Clin Anesth. 2009 Sep 1;21(6):444–453.
   PubMed Web of Science ®Google Scholar
• Asztalos L, Szabó-Maák Z, Gajdos A, et al. Reversal of vecuronium-induced neuromuscular blockade with low-dose sugammadex at train-of-four count of four: a randomized controlled trial. Anesthesiology. 2017 Sep;127(3):441–449.
   PubMed Web of Science ®Google Scholar
• Grigg E. Sugammadex and neuromuscular reversal: special focus on neonatal and infant populations. Curr Opin Anesthesiol. 2020 Jun 1;33(3):374–380.
   PubMed Web of Science ®Google Scholar
• Blobner M, Eriksson LI, Scholz J, et al. Della Rocca G Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anesthesiol. 2010;27:874–881.
   PubMed Web of Science ®Google Scholar
• Suy K, Morias K, Cammu G. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007;106(2):283–288.
   PubMed Web of Science ®Google Scholar
• Bilgi M, Demirhan A, Akkaya A, et al. Sugammadex associated persistent bradycardia. Int J Med Sci Public Health. 2015;3:372e4.
   Google Scholar
• Bhavani SS. Severe bradycardia and asystole after sugammadex: a report of 2 cases. Br J Anaesth 2018; 121: 95e6
   Google Scholar
• Hristovska AM, Duch P, Allingstrup M, et al. safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017;8(8):Cd012763.
   PubMedGoogle Scholar
• Fierro C, Medoro A, Mignogna D, et al. Bradycardia and Asystole after Sugammadex Administration in an Elderly Patient. Medicina (B Aires). 2021;57(1):79.
   Google Scholar
• Eriksson LI. Evidence-based practice and neuromuscular monitoring: it’s time for routine quantitative assessment. Anaesthesiol. 2003;98(5):1037–1039.
   PubMed Web of Science ®Google Scholar
• Gaszynski T, Jakubiak J, Szlachcinski L, et al. Administration of neostigmine does not prevent from post-operative residual curarisation. Eur J Anaesthesiol. 2008;25(Sup 44):137.
   Google Scholar
• Tanaka M, Sato M, Saito A, et al. Reevaluation of rectal ketamine premedication in children. Anesthesiology. 2000;93(5):1217–1224.
   PubMed Web of Science ®Google Scholar
• Won YJ, Lim BG, Lee DK, et al. Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients: a systematic review and meta-analysis. In: Medicine. Vol. 95 (Wolters Kluwer Health); 2016 Aug. p. 34.
   Google Scholar
• Liu G, Wang R, Yan Y, et al. The efficacy and safety of sugammadex for reversing postoperative residual neuromuscular blockade in pediatric patients: a systematic review. Sci Rep. 2017 Jul 18;7(1):1–9.
   PubMedGoogle Scholar
• Alonso A, de Boer HD, Booij L. Reversal of rocuronium-induced neuromus- cular block by sugammadex in neonates. Eur J Anaesthesiol. 2014;31(Suppl52): 163–165 .
   Web of Science ®Google Scholar
• Franz A, Chiem J, Martin LM, et al. Case Series of 331 doses of Sugammadex compared to Neostigmine in patients under 2-years-old. Pediatr Anesth. 2019;29(6):591–596.
   PubMed Web of Science ®Google Scholar
• An J, Lee JH, Kim E, et al. Comparison of sugammadex and pyridostigmine bromide for reversal of rocuronium-induced neuromuscular blockade in short-term pediatric surgery: a prospective randomized study. In: Medicine. Vol. 99 (wolters Kluwer Health); 2020 Feb. p. 7.
   Google Scholar
• Ammar AS, Mahmoud KM, Kasemy ZA. A comparison of sugammadex and neostigmine for reversal of rocuronium‐induced neuromuscular blockade in children. Acta Anaesthesiol Scand. 2017 Apr;61(4):374–380.
   PubMed Web of Science ®Google Scholar
• Katz RL. Pyridostigmin (mestinon) as an antagonist of d-tubocurarine.J American SocAnesthesiologists 1967 May 1 (Vol. 28, No. 3, pp. 528–534). The American Society of Anesthesiologists
   Google Scholar
• Abrishami A, Ho J, Wong J, et al. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. In: Cochrane Database of Systematic Reviews (john wiley & Sons). 2009. p. 4.
   Google Scholar
• Gaver RS, Brenn BR, Gartley A, et al. Retrospective analysis of the safety and efficacy of sugammadex versus neostigmine for the reversal of neuromuscular blockade in children. Anesthesia Analg. 2019 Oct 1;129(4):1124–1129.
   PubMed Web of Science ®Google Scholar
• Simonini A, Brogi E, Calevo MG, et al. Sugammadex for reversal of neuromuscular blockade in paediatric patients: a two-year single-centre retrospective study. Anaesth Crit Care Pain Med. 2019 Feb 25;38(5):529–531.
   PubMed Web of Science ®Google Scholar
• Lang B, Han L, Zeng L, et al. safety of sugammadex for neuromuscular blockade reversal in pediatric patients: an updated meta-analysis of randomized controlled trials with trial sequential analysis. BMC Pediatr. 2022 Dec;22(1):1–2.
   PubMed Web of Science ®Google Scholar